Lidocaine inhibits the proliferation of lung cancer by regulating the expression of GOLT1A

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Lidocaine is the most commonly used local anaesthetic in clinical and can inhibit proliferation, suppress invasion and migration and induce apoptosis in human lung adenocarcinoma ( LAD ) cells. However, its specific downstream molecular mechanism is unclear. LAD cell lines, A549 and H1299 cells, were treated with lidocaine. The proliferation was evaluated by the methylthiazolyldiphenyl‐tetrazolium bromide ( MTT ) and bromodeoxyuridine (BrdU) assay. The expression level of related proteins was detected by real‐time quantitative PCR ( qPCR ) and Western blot assay. The results indicated that lidocaine dose‐dependently suppressed the proliferation of A549 and H1299 cells. In the LAD patients’ samples, GOLT 1A was upregulated and involved in the poor prognosis and higher grade malignancy. Additionally, GOLT 1A mediates the function of lidocaine on repressing proliferation by regulating the cell cycle in A549 cells. Our findings suggest that lidocaine downregulates the GOLT 1A expression to repress the proliferation of lung cancer cells.

Related collections

Most cited references 36

Record: found
Abstract: found
Article: not found

Non-small-cell lung cancers: a heterogeneous set of diseases.

Zhao Chen, Christine Fillmore, Peter Hammerman … (2014)

Non-small-cell lung cancers (NSCLCs), the most common lung cancers, are known to have diverse pathological features. During the past decade, in-depth analyses of lung cancer genomes and signalling pathways have further defined NSCLCs as a group of distinct diseases with genetic and cellular heterogeneity. Consequently, an impressive list of potential therapeutic targets was unveiled, drastically altering the clinical evaluation and treatment of patients. Many targeted therapies have been developed with compelling clinical proofs of concept; however, treatment responses are typically short-lived. Further studies of the tumour microenvironment have uncovered new possible avenues to control this deadly disease, including immunotherapy.

0 comments Cited 459 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Biomarkers for the early diagnosis of hepatocellular carcinoma.

Nobuhiro Tsuchiya, YU SAWADA, Itaru Endo … (2015)

Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading cause of cancer-related deaths worldwide. Although the prognosis of patients with HCC is generally poor, the 5-year survival rate is > 70% if patients are diagnosed at an early stage. However, early diagnosis of HCC is complicated by the coexistence of inflammation and cirrhosis. Thus, novel biomarkers for the early diagnosis of HCC are required. Currently, the diagnosis of HCC without pathological correlation is achieved by analyzing serum α-fetoprotein levels combined with imaging techniques. Advances in genomics and proteomics platforms and biomarker assay techniques over the last decade have resulted in the identification of numerous novel biomarkers and have improved the diagnosis of HCC. The most promising biomarkers, such as glypican-3, osteopontin, Golgi protein-73 and nucleic acids including microRNAs, are most likely to become clinically validated in the near future. These biomarkers are not only useful for early diagnosis of HCC, but also provide insight into the mechanisms driving oncogenesis. In addition, such molecular insight creates the basis for the development of potentially more effective treatment strategies. In this article, we provide an overview of the biomarkers that are currently used for the early diagnosis of HCC.

0 comments Cited 212 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Management of non-small-cell lung cancer: recent developments.

Jean-Charles Soria, Tony Mok, K. F. Rabe … (2013)

Non-small-cell lung cancer is one of the leading causes of deaths from cancer worldwide. Therefore, improvements in diagnostics and treatments are urgently needed. In this review, we will discuss the evolution of lung cancer staging towards more non-invasive, endoscopy-based, and image-based methods, and the development of stage-adapted treatment. A special focus will be placed on the role of novel surgical approaches and modern radiotherapy strategies for early stages of disease, the effect of multimodal treatment in locally advanced disease, and ongoing developments in the treatment of patients with metastatic disease. In particular, we will include an emphasis on targeted therapies, which are based on the assumption that a treatable driver mutation or gene rearrangement is present within the tumour. Finally, the position of lung cancer treatment on the pathway to personalised therapy will be discussed. Copyright © 2013 Elsevier Ltd. All rights reserved.

0 comments Cited 95 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Hong Jiang: (View ORCID Profile)

Journal

Title: Cell Proliferation

Abbreviated Title: Cell Prolif

Publisher: Wiley

ISSN: 09607722

Publication date Created: October 2017

Publication date (Print): October 2017

Publication date (Electronic): July 24 2017

Volume: 50

Issue: 5

Page: e12364

Affiliations

[1 ]Department of Anesthesiology; Shanghai Ninth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; Center for Specialty Strategy Research of Shanghai Jiao Tong University China Hospital Development Institute; Shanghai China